InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.00%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.36
(
0.03%
)
Bitcoin
54,102.57
(
-5.05%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

rkrw

Send PM Follow Ignore
Followers 45
Posts 3204
Boards Moderated 0
Alias Born 12/29/2003

rkrw

Member Level

Re: raistthemage post# 14855

Monday, 11/03/2008 3:23:41 PM

Monday, November 03, 2008 3:23:41 PM

Post# of 19309
I was just busting your chops. Lighten up.

gtcb really doesn't spend tons of money in biotech land. They did have a flawed business plan with their lead program as Atryn. Sales potential was too small to mean anything for investors. They had always thought get something approved and that's the proof of concept, partners will line up. Meanwhile they should have focused on something with more upside. Even if Atryn gets approved and I don't think it will on its first pass. Yawn. imo.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up